Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-FR | Version v1-EN | |
|---|---|---|
| Language (Changed) | Updated to: French | Was: English |
| Date Updated | 2026-02-25 | 2026-02-25 |
| Drug Identification Number | 02501554 | 02501554 |
| Brand name | FENTANYL CITRATE INJECTION, USP | FENTANYL CITRATE INJECTION, USP |
| Common or Proper name | Fentanyl Citrate, USP 50 mcg/mL, 1 mL vial | Fentanyl Citrate, USP 50 mcg/mL, 1 mL vial |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | FENTANYL | FENTANYL |
| Strength(s) | 50MCG | 50MCG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR EPIDURAL | INTRAVENOUS INTRAMUSCULAR EPIDURAL |
| Packaging size | 1 mL | 1 mL |
| Additional packaging sizes | ||
| ATC code | N01AH | N01AH |
| ATC description | ANESTHETICS, GENERAL | ANESTHETICS, GENERAL |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2026-04-01 | 2026-04-01 |
| Actual start date | ||
| Estimated end date | 2026-06-23 | 2026-06-23 |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada regrets to advise that due to a delay in production, we will be encountering a supply interruption on the following products. Please refer to the following table for details. | Fresenius Kabi Canada regrets to advise that due to a delay in production, we will be encountering a supply interruption on the following products. Please refer to the following table for details. |
| Health Canada comments |